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This study examined the immunogenic properties of the fusion protein fimbria 2 of Bordetella pertussis (Fim2)—cholera toxin B
subunit (CTB) in the intranasal murine model of infection. To this end B. pertussis Fim2 coding sequence was cloned downstream
of the cholera toxin B subunit coding sequence.The expression and assembly of the fusion protein into pentameric structures (CTB-
Fim2) were evaluated by SDS-PAGE and monosialotetrahexosylgaglioside (GM1-ganglioside) enzyme-linked immunosorbent
assay (ELISA). To evaluate the protective capacity of CTB-Fim2, an intraperitoneal or intranasal mouse immunization schedule
was performed with 50𝜇g of CTB-Fim2. Recombinant (rFim2) or purified (BpFim2) Fim2, CTB, and phosphate-buffered saline
(PBS) were used as controls. The results showed that mice immunized with BpFim2 or CTB-Fim2 intraperitoneally or intranasally
presented a significant reduction in bacterial lung counts compared to control groups (𝑃 < 0.01 or 𝑃 < 0.001, resp.). Moreover,
intranasal immunization with CTB-Fim2 induced significant levels of Fim2-specific IgG in serum and bronchoalveolar lavage
(BAL) and Fim2-specific IgA in BAL. Analysis of IgG isotypes and cytokines mRNA levels showed that CTB-Fim2 results in a
mixed Th1/Th2 (T-helper) response. The data presented here provide support for CTB-Fim2 as a promising recombinant antigen
against Bordetella pertussis infection.
1. Introduction
Pertussis or whooping cough is an acute respiratory disease
whose principal etiological agent is the gram-negative bac-
terium Bordetella pertussis [1]. The clinical manifestations
are more severe in infants than in adolescents or adults,
who are now recognized as the main source of infection [2].
The best way to prevent pertussis is vaccination with either
whole cellular (wP) or acellular (aP) vaccines [3]. Protective
immunity generated by wP appears to be mediated largely by
Th1 cells, whereas less efficacious alum-adjuvanted aP induce
strong antibodyTh2 responses [4].
Despite widespread pertussis immunization in childhood
for more than 50 years, pertussis is considered to be the
most poorly controlled bacterial vaccine-preventable disease
[5] and remains an endemic disease with regular epidemics
[6]. Currently, there are an estimated 16 million cases and
195,000 deaths due to pertussis globally each year, most of
them in developing countries [1]. The most vulnerable to the
disease correspond to groups of unvaccinated infants, par-
tially vaccinated children, and persons who have completed
the immunization schedule with waning immunity [1]. In
addition, since the early 1980s there has been an increase in
reported cases of pertussis [5], even in countries with a high
vaccination coverage rate [7].Waning immunity conferred by
vaccines, increased recognition, changes in diagnostic testing
and reporting, and adaptation of the agent to immunity
induced by vaccines are some of the factors that may have
contributed to this increase [5].
Taken together, it is clear that additional vaccine
approaches are needed. Some of the new approaches under
trial include vaccination of newborns and additional booster
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doses for older adolescents and adults. Innovative vaccines
are also being studied [1]. In this regard, since infection by
B. pertussis is usually restricted to the airways, an interesting
alternative may be mucosal vaccination [8, 9]. It has been
shown that mucosal vaccination is the best way to achieve
a strong cellular and humoral immune response in airways
as well as systemically [10]. There are also important logistic
reasons that have made mucosal immunization attractive
for public health use. Mucosal vaccines should be easier
and cheaper to administer than parenteral vaccines and also
have a lower risk of transmitting hepatitis B virus and HIV
infections [11].
However, most protein antigens are poorly immunogenic
and potent adjuvants are often needed to enhance immunity
[12]. The cholera toxin B subunit (CTB) is among the most
potent mucosal adjuvants known [13, 14]. CTB is the pen-
tameric nontoxic portion of cholera toxin (CT) responsible
for the binding of the holotoxin to the monosialotetrahexo-
sylgaglioside (GM1 ganglioside) receptor [15]. Chemical and
genetic conjugations of CTBwith different heterologous anti-
gens from simian immunodeficiency virus and Schistosoma
mansoni, among others, have shown promising results [16,
17].
The fimbriae (Fim) proteins are promising as immuno-
gens to be used by the mucosal route because they act as
pathogen-associated molecular patterns (PAMPs) [18, 19]
and, in the case of Fim2 and 3 of B. pertussis, have known
immunogenic properties and although Fim3 seems to exhibit
lower protective capacity than Fim2 when isolated from B.
pertussis, both have justified their presence in most recent
acellular vaccines [20, 21].
In this study, we constructed a histidine-tagged
CTB-Fim2 fusion protein in order to evaluate its protective
capacity and immunogenic properties in a B. pertussis
respiratory infection murine model. The results presented
here showed that CTB-Fim2 is a promising antigen against
B. pertussis infection.
2. Materials and Methods
2.1. Strain and Growth Conditions. The Escherichia coli strain
DH5𝛼 (Invitrogen, USA) was used for all routine cloning
experiments, whereas the BL21(SI) and BL21Star (DE3) E. coli
competent cells (Invitrogen) were used for recombinant
protein expression. The B. pertussis strain used in this study
was Tohama phase I [22–24] obtained from the Pasteur
Institute, Paris, France. The strain from glycerol stock was
cultured onBordet-Gengou agar (BGA,Difco) supplemented
with 1% glycerol and 10% (v/v) defibrinated sheep blood and
incubated at 36∘C for 3 days. The bacteria was then replated
in the samemedium for 24 h and the subcultures were grown
in Stainer-Scholte liquid medium (SS) [25], with shaking at
36∘C for 20 h.
2.2. Cloning of Recombinant Proteins. The fim2 (621 bp)
gene, from B. pertussis strain Tohama phase I, was amplified
from genomic DNA by PCR. The mixture was subjected
to a program consisting of a DNA denaturation step at
94∘C for 2min, 35 cycles at 94∘C for 15 s, 48∘C for 15 s, and
72∘C for 40 s. The following oligonucleotides were used
for cloning into pET-TOPO 200 and pAEctxB plasmids,
respectively: Fim2F 5󸀠CACCATGCCATTGATCTCG3󸀠 and
Fim2R 5󸀠TTCGCTCCTGCATGGAATAC3󸀠; CTBFim2F
5󸀠TGGTTCACGCGTATGTTACCCATGCAAATCCC3󸀠
and CTBFim2R 5󸀠CTGATAAGCTTCTAGGGGTAGACCA
CGG3󸀠. In bold are the MluI and HindIII restriction
sites, respectively. The amplified products were cloned
into pET-TOPO 200 vector and transferred to pDEST17
according to the manufacturer’s instructions (Invitrogen)
or into pAE-ctxB [26] using the MluI and HindIII sites in
order to generate the pDEST17-fim2 and pAE-ctxB-fim2
plasmids. The recombinant clones were confirmed by PCR
and sequenced.
2.3. Expression and Purification of the Recombinant Proteins.
The expression and purification of rFIM2 and CTB-Fim2
was performed as previously described for other recombinant
proteins [27, 28]. Briefly, BL21(SI) E. coli competent cells
were transformed with the pDEST17-fim2 or pAE-ctxB-fim2
plasmids and grown overnight (ON) at 37∘C. Ampicillin-
resistant colonies were inoculated in 5mL on Luria Bertani
(LB) medium with ampicillin (50 𝜇g/mL) without NaCl and
grown ON at 37∘C. On the following day, cultures were
diluted 50-fold in LB-amp without NaCl and grown until
A
600
reached 0.8, when NaCl was added to the medium
at a final concentration of 300mM. After 3 h, cells were
collected by centrifugation, resuspended in 10mL lysis buffer,
pH 8.0 (Tris-Cl 20mM and NaCl 100mM), and lysed by
sonication. Cellular lysates were centrifuged at 14,000 rpm for
30min. Both recombinant proteins were recovered from the
inclusion bodies and solubilized with 10mL of solubilization
buffer (8M urea, 50mM Tris-Cl, 500mM NaCl, pH 8.0).
The material was then dialyzed against 2 L of refolding buffer
(500mM NaCl, 50mM Tris-Cl, pH 8.0). Refolded protein
solution was adsorbed to the Ni2+-NTA resin (Invitrogen)
and washed with ten volumes of binding buffer (100mM
NaCl, 20mM Tris-Cl, pH 8.0) containing 5, 20, 40, and
60mM imidazole.The proteins were eluted with five volumes
of the same solution containing 250mM imidazole. Fractions
were analyzed by 10% SDS-PAGE. The purified proteins
were dialyzed in one step. The equilibrium was established
using 2 L of a 10mM Tris-Cl, pH 8.0, 20mM NaCl, and
0.1% (m/v) glycine solution. The identity of the expressed
protein and its molecular weight were confirmed byMALDI-
TOF mass spectrometry. Searches for and the identification
of peptides were performed using a licensed version of
MASCOT software (Matrix Science) with a peptide tolerance
of 50 ppm. Monoisotopic peptide masses were used to search
the database, allowing a molecular mass range for 2-DE
analyses of 15%. Purified CTB was purchased from Sigma
(Argentina). For immunogenicity studies, contaminant LPS
was removed from aliquots of recombinant proteins using
the Detoxi-Gel Endotoxin Removing Gel columns (Thermo
Scientific-Pierce, USA), according to the manufacturer’s
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instructions. The purification of BpFim2 was similar to a
procedure described elsewhere [29].
2.4. Limulus Amebocyte Lysate Assay (LAL Test). The chro-
mogenic LAL assay for endotoxin activity of the protein sam-
ples was performed using the QCL-1000 kit (Bio-Whittaker,
MD), according to the manufacturer’s instructions. In all
cases, the final LPS content was less than 5 × 10−6 𝜇g/mL.
2.5. Immunoblotting. The immunoblot analysis (IB) was per-
formed as previously described [28]. Briefly, aliquots were
subjected to SDS-PAGEand then transferred to nitrocellulose
membranes (GE Healthcare). Membranes were blocked with
5% nonfat dried milk in PBS containing 0.05% Tween
20 (PBS-T) and then incubated with a mouse antiserum
(1 : 2500) against CTB in 5% nonfat dried milk/PBS-T for
2 h at RT. After washing, the membrane was incubated with
HRP-conjugated anti-mouse IgG (1 : 5000; Sigma) in 5%
nonfat dried milk/PBS-T for 1 h. The bands were revealed
with ECL reagent kit chemiluminescence substrate (GE
Healthcare).
2.6. Pentamer Analysis Assays. To determine whether
CTB-Fim2 folds into pentamers during SDS-PAGE, samples
were subjected to denaturing and nondenaturing conditions.
In the latter case, samples were not boiled, and the sample
buffer used did not contain 𝛽-mercaptoethanol. The ability
of the CTB pentamers to bind to their cellular receptor
was assessed using a GM1-ELISA assay. This protocol was
adapted from a previously published study [28]. Briefly, 96-
well plates (Nunc) were coated with 0.5 𝜇g per well (100 𝜇L)
of GM1 (Sigma) in PBS, pH 7.4 at 4∘C for 16 h. As a negative
control, the wells were coated with bovine serum albumin
(BSA) at the same concentration (5 𝜇g/mL) in PBS pH 7.4.
Commercial CTB was used as a positive control. Plates were
blocked and then washed five times. Afterwards, the wells
were incubated with 100 𝜇L of the recombinant protein
serially diluted in PBS 1/2 from ∼300 nM to 146 pM for 2 h
at 37∘C and then washed. Microtiter plates were incubated
for 1 h at 37∘C with a 1/2500 dilution of a polyclonal
anti-CTB serum [28] in 5% nonfat dried milk/PBS-T and
washed.Thereafter, they were incubated with the anti-mouse
conjugated to HRP (Santa Cruz Biotechnology, USA) diluted
1/4000 for 1 h at 37∘C. After washing, plates were revealed by
the addition of 10mg o-phenylenediamine (OPD) in 10mL
of a 0.2M citrate-phosphate buffer, pH 5.0, in the presence
of 10 𝜇L of H
2
O
2
. The reaction was stopped by the addition
of 4M H
2
SO
4.
The absorbance was measured at 492 nm in
all cases.
2.7. Immunization of Mice and Sample Collection. Groups
of 4–8 and 3-4 week-old female BALB/c mice (Instituto
Biolo´gico Argentino, Argentina) received 50 𝜇g of purified
CTB-Fim2 intraperitoneal or intranasally in 50𝜇L of PBS on
days 0, 12, and 24 with aluminum hydroxide as an adjuvant
(0.2mg/mL, IP) or without external adjuvant (IN). Mice
immunized with CTB (5 𝜇g, IN only), rFim2, or BpFim2
alone (50𝜇g) and mice inoculated with 50 𝜇L of PBS were
used as control groups.
Blood samples were obtained from a facial vein at days
12, 24, and 36, and the obtained sera were stored at −20∘C.
BAL fluid was collected postmortem after the challenge by
flushing the lungs twice with PBS. An incision was made in
the neck, so as to expose the trachea. Using a 5mL syringe,
1mL of PBS was slowly introduced into the lungs via the
trachea and then syringed out. This was repeated twice. The
protease inhibitor phenylmethylsulfonyl fluoride (Sigma)was
added to each sample at a concentration of 1mM following
collection, and samples were kept at −20∘C until use. At
least two independent experiments were performed with
consistent results.
2.8. Antibody Determination by ELISA. Ninety-six well plates
were coated with 5 𝜇gmL−1 of rFim2/well in carbonate-
bicarbonate buffer, pH 9.6 at 4∘CON.The plates were washed
three times with PBS-T. Nonspecific binding was reduced by
blocking the plates with 300 𝜇L/well of 5% nonfat milk/PBS-
T (m/V) at 37∘C for 1 h. The plates were washed three times
with PBS-T. Samples that were to be tested for Fim2-specific
antibodies were diluted 1/20 for sera IgG, IgG1, IgG2a, and
IgA (the mucosal fluids were not previously diluted) in PBS-
T, with 50𝜇L being added to the plate in duplicate and
serially diluted 2-fold down the plate. A final 1/64 dilutionwas
used for comparison and graphical purposes.The plates were
incubated at 37∘C for 1 h and then washed three times with
PBS-T. Bound antibodies were detected using at appropri-
ate dilutions commercial peroxidase conjugated anti-mouse,
IgG, IgG1a, IgG2, and IgA (Santa Cruz Biotechnology). The
subsequent steps were performed as described in GM1-
ELISA.
2.9. Protection Assay in a Mouse Respiratory Model. The
challenge assay was performed using the mouse respiratory
model of B. pertussis infection as described previously [30].
Briefly, cohorts of BALB/cmicewere immunized as described
above, and 12 days after the last dose of immunization,
they were challenged with a suspension of 5 × 107 CFU
of virulent B. pertussis in 50 𝜇L of PBS. Inoculation was
performed by pipetting the inoculum into the nostrils.
Animals were euthanized by CO
2
overdose 8 days postin-
fection (PI), and the lungs were excised. Left lung was
used for bacterial recovery as described previously [30],
and the right lung was split in two samples, one used
for cytokine level and the other for routine histological
examination.
All animal experiments were performed according to our
Institute’s Ethical Committee and the National Institutes of
Health guidelines [31].
2.10. RNA Isolation and RT-PCR. Total RNA was isolated
from lung tissue by mechanical homogenization in Trizol
reagent (Invitrogen, Argentina), as recommended by the
manufacturer. DNase treatment was performed with an
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RNase-free DNase Kit (Qiagen, Germany). cDNA was syn-
thesized from 500 ng of total RNA with 15mM of random
hexamers and SuperScript III reverse transcriptase (Invit-
rogen, Argentina), according to the manufacturer’s instruc-
tions.
2.11. Real-Time PCR. All q-PCR studies were performed
with a Line-Gene instrument (Bioer Technology, China).
The TAQurate green real-time PCR MasterMix (Epicentre
Biotechnologies) was used for all reactions, following the
manufacturer’s instructions. Initial denaturation was carried
out at 94∘C for 10min, followed by 65 cycles of 20 s at
94∘C, 15 s at the respective annealing temperatures and 15 s
at 72∘C each, and a final extension at 72∘C for 2min. A
melting curve analysis was performed immediately after
amplification at a linear temperature transition rate of
0.3∘C/s from 70∘C to 89∘C with continuous fluorescence
acquisition. The size of all PCR products was confirmed by
agarose gel electrophoresis. Transcription levels of IL-4 (F
5󸀠CATCGGCATTTTGAACGAGGTCA3󸀠; R 5󸀠CTTATC-
GATGAATCCAGGCATCG3󸀠); and IFN-𝛾 (F 5󸀠CTTGGA-
TATCTGGAGGAACTGGC3󸀠; R 5󸀠GCGCTGACCTGT-
GGGTTGTTGA3󸀠) were measured in all samples and
normalized to 𝛽-actin levels (F 5󸀠GCTTCTTTGCAGCTC-
CTTCGT3󸀠; R 5󸀠CATTCATGTTTCGAATCATTTCAAA3󸀠).
2.12. Statistical Analysis. A one-way ANOVA test was used
to determine significant differences in the assays, and data
are expressed as mean ± SEM. When necessary, data were
analyzed by one-way analysis of variance followed by the
Bonferroni multiple comparison test to determine significant
differences between groups. 𝑃 < 0.05 was considered
statistically significant.
3. Results
3.1. Expression and Purification of CTB-Fim2. The design
used to construct the recombinant plasmid is illustrated in
Figure 1(a). The fusion protein was expressed and purified as
described previously [28]. The results are shown in Figures
1(b) and 1(c), respectively. As expected, the molecular weight
of CTB-Fim2 was 36 kDa. The presence of CTB in the
fusion protein was confirmed by immunoblotting using a
murine anti-CTB antiserum (Figure 1(d)) and by MALDI-
TOF mass spectrometry. While a positive result was detected
for CTB-Fim2, no band was detected in the nontransformed
E. coli extract or when the primary antibody was omitted
(data not shown). These data demonstrated that the recom-
binant E. coli harboring the plasmid express the recombinant
protein recognizable by anti-CTB antibodies.
3.2. Pentamer Conformation of CTB-Fim2. The oligomeric
structure of CTB-Fim2 was analyzed by gel electrophoresis.
Figure 2(a) (lane 1) shows that CTB-Fim2, previously sol-
ubilized in denaturing Laemmli sample buffer and boiled,
migratedwith aMWof 36 kDa. In contrast, when proteinwas
solubilized in nondenaturing Laemmli sample buffer without
boiling (lane 2) it migrated with a MW of 180 kDa. These
His tag Cholera toxinB subunit Fimbria 2
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Figure 1: Immunogen design, expression, purification, and
immunoblot analysis of the CTB-Fim2 fusion protein. (a) Schematic
representation of immunogen design. (b) Protein expression and
purification in the E. coli (SI) strain transformed with pAE-CTB-
Fim2. Protein expression was assayed using a 10% SDS-PAGE
gel and shows a 36 kDa band. (c) Analysis of the recombinant
CTB-Fim2 protein after elution from Ni2+-charged beads with
250mM imidazole. (d) Reactive protein bands probed with a mouse
antiserum (1 : 2500) against CTB. NI and I stand for noninduced
and induced bacterial extract, respectively.
results suggest that native CTB has a pentameric structure
after the refolding process.
The pentameric conformation was also evaluated by its
ability to bind to its receptor GM1-ganglioside in an ELISA
assay since monomeric CTB has a low affinity for GM1 [32].
For detection, anti-CTB serum was used (Figure 2(b)). The
results showed that commercial CTB and purified CTB-Fim2
were similarly able to bind GM1 in a concentration-specific
manner. These results strongly suggest that CTB-Fim2 has a
pentameric structure and indicate that the presence of Fim2
does not abrogate either the formation of the pentamer or
binding to its GM1 receptor.
3.3. Protective Capacity of CTB-Fim2. To evaluate the pro-
tective capacity against B. pertussis infection of CTB-Fim2
immunization, we employed a previously described mice
model [30]. Balb/c mice were immunized intraperitoneally
or intranasally three times with (50𝜇g/dose) the recombi-
nant CTB-Fim2, rFim2, and BpFim2 and were challenged
with a 5 ⋅ 107 CFU of virulent B. pertussis Tohama phase I
strain/50 𝜇L suspension inPBS 12 days following the last dose.
Mice treated with CTB (5 𝜇g, IN only) or 50𝜇L of PBS were
used as negative controls.
The results obtained at 8 days after the challenge showed a
significant reduction in bacterial counts in mice immunized
either by the intraperitoneal or the intranasal route with
CTB-Fim2 compared to the controls treatedwith PBS or CTB
(IP 3.7 ± 0.2 versus 5.3 ± 0.2 logs CFU/lung, 𝑃 < 0.01) or (IN
3.2 ± 0.2 versus 4.9 ± 0.1 logs CFU/lung, 𝑃 < 0.001), respec-
tively. In contrast, intraperitoneal or intranasal immunization
with rFim2 did not significantly reduce the bacterial counts
in lungs compared to control groups (4.8 ± 0.1 and 5.3 ± 0.1
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Figure 2: Pentamer formation of CTB-Fim2. (a) SDS-PAGE with
purified CTB-Fim2. Lane 1 is the sample boiled in reducing condi-
tions while lane 2 is the same protein sample not subjected to boiling
and in nonreducing conditions. Bands of 36 and 180 kDa of CTB-
Fim2 are shown, respectively. (b) GM1-ELISA to verify the ability
of the pentamer to bind GM1-ganglioside using recombinant CTB-
Fim2. Commercial CTB was used as a positive control. The 96-well
plates were coated with GM1 or BSA and mouse anti-CTB antisera
(1 : 2500).
logs CFU/lung, resp.). As expected, a significant decrease
was seen between BpFim2, isolated from B. pertussis and
used as a positive control, and control groups either by the
intraperitoneal or the intranasal route (𝑃 < 0.001) (Figure 3).
There were no statistically significant differences between
mice immunized intraperitoneally or intranasally with
CTB-Fim2 (3.7 ± 0.2 versus 3.2 ± 0.2 CFU/lung).
These results indicate that intraperitoneal or intranasal
administration of CTB-Fim2 was effective in protecting
mice against intranasal challenge with B. pertussis with a
dose of 50 𝜇g of immunogen. Moreover, CTB improved the
protective capacity of rFim2 when it was genetically fused to
the antigen.
3.4. Serum IgG Levels Following Immunization. To further
characterize the immunogenic properties of CTB-Fim2, we
study the humoral response induced in serum samples col-
lected during the intraperitoneal or intranasal immunization
protocols, by ELISA. As expected, the specific humoral
response increased after each immunization in all groups.
To simplify the analysis, only the values of serum IgG at
day 35, one day before challenge with B. pertussis, are shown
(Figure 4). Either intraperitoneal or intranasal immunization
with rFim2 or CTB-Fim2 generated a specific serum IgG
response (DO at 492 nm = 0.9 and 0.6, resp., for rFim2;
0.9 or 1.2 for CTB-Fim2, resp.; 𝑃 < 0.01 and 0.001,
resp.) (see Figure 4). These results show that meanwhile
rFim2 and CTB-Fim2 generated similar levels of anti-Fim2
serum IgG after intraperitoneal immunization, the level of
anti-Fim2 serum IgG elicited by CTB-Fim2 after intranasal
immunization was significantly higher.
3.5. Humoral Response in BALWashes. To assess the immune
responses at the mucosal surface, groups of mice were
immunized intranasally or intraperitoneally three times with
PBS, CTB, rFim2, or CTB-Fim2 every 12 days followed by
intranasal challenge with B. pertussis Tohama phase I strain
(5 × 107 CFU/mouse). At 8 days postinfection animals were
euthanized and BALwashes were collected for determination
of anti-Fim2 IgG (a) and IgA (b) antibodies (Figure 5). Anti-
body levels were assayed using ELISA. Values represent the
OD at 492 nm and are representative of two separate exper-
iments ( ∗𝑃 < 0.05 versus CTB-Fim2 IP, ∗∗𝑃 < 0.001 and
∗∗∗
𝑃 < 0.0001 versus PBS, CTB, and rFim2 IN, ∘𝑃 < 0.05
versus PBS and CTB, +𝑃 < 0.05 versus PBS, CTB, and rFim2
IN and IP, and ++𝑃 < 0.001 versus CTB-Fim2 IP).
These results mainly indicate that rFim2, when
administered intranasally, was not capable of
generating a strong humoral response in BAL, but
when CTB was genetically fused to the antigen,
specific antibody levels significantly increased in BAL,
giving high titers of IgG and IgA with the fusion
protein.
3.6. Analysis of Th Cell Response. To gain partial insight
into the nature of immune responses induced by intranasal
immunization with CTB-Fim2, we first quantified serum IgG
subtypes G1 and G2a specific to Fim2 at day 36 postim-
munization and before challenge (Figure 6). In agreement
with specific total IgG response values found in serum,
significantly higher levels of IgG1 antibodies were detected in
the rFIM2 andCTB-Fim2 groups comparedwith the negative
controls (DO at 492 nm = IgG1: 1.1 and 1.3, resp.; 𝑃 < 0.05).
In contrast, the IgG2a anti-Fim2 levels were only elevated by
CTB-Fim2 (DO at 492 nm = IgG2a: 0.4 and 1.8, resp., 𝑃 <
0.01). On the other hand, analysis of IFN-𝛾 and IL-4 mRNA
levels (Figure 7) showed that meanwhile rFim2 and CTB-
Fim2 induce an increase of IL-4, only CTB-Fim2 induces
a significant increase of IFN-𝛾 in the lung of immunized
mice compared with the negative controls. In addition, the
histopathology analysis (Figure 8) showed a more intense
inflammation in the lungs of mice immunized with CTB-
Fim2 compared with the rFim2 and negative control groups.
The enhanced inflammatory response detected at day 8 after
6 BioMed Research International
IP
0
1
2
3
4
5
6
Lo
g 1
0
(C
FU
/lu
ng
)
PBS rFim2 CTB-Fim2
∗∗
(a)
0
1
2
3
4
5
6
Lo
g 1
0
(C
FU
/lu
ng
)
PBS
IN
CTB rFim2 BpFim2 CTB-Fim2
∗∗∗ ∗∗∗
(b)
Figure 3: Protective capacity of CTB-Fim2. Groups of animals were immunized (a) intraperitoneally or (b) intranasally three times with PBS,
CTB (IN only), rFim2, BpFim2, or CTB-Fim2 every 12 days followed by IN challenge with 5 × 107 UFC of the Tohama I strain of B. pertussis.
At 8 days postinfection, animals were killed and lung samples were collected for UFC counting. Each point represents the mean (± standard
error) of 8 animals ( ∗∗𝑃 < 0.001 versus PBS; ∗∗∗𝑃 < 0.0001 versus PBS, CTB, and rFim2).
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Figure 4: Specific IgG antibodies in serum. Induction of serum anti-Fim2 IgG after intraperitoneal (a) or intranasal (b) immunization with
PBS, CTB, rFim2, and CTB-Fim2. Anti-Fim2 IgG titers of individual serum collected immediately before challenge on day 36 are shown.
Values represent the OD at 492 nm and show the mean (±standard error) of 8 animals ( ∗∗𝑃 < 0.001 versus rFim2 IN; ∗∗∗𝑃 < 0.0001 versus
PBS and CTB IN and IP).
the challenge was not deleterious for the animal evaluated
as survival or presence of symptoms, including lethargy,
hypothermia, or changes in nose/mucosal surfaces.
4. Discussion
Natural infection with B. pertussis induces strong and long-
lasting immunity that wanes later than vaccine-induced
immunity [33]. The use of the mucosal route of vaccination
is an attractive alternative to the use of the parenteral route
since it may mimic many aspects of the immune response
elicited against the natural infection [34]. Moreover, a single
nasal dose of a live attenuatedB. pertussiswas effective against
whopping cough in the murine model [35]. In addition,
other pertussis antigens such as pertactin and filamentous
hemagglutinin or even the more complex component, the
outer membrane vesicles administered via the mucosal route,
has proven to be effective against B. pertussis infection [36,
37], showing that mucosal vaccination may constitute a
possible alternative to the widely used parenteral route.
The presence of fimbriae (serotypes 2 and 3) in acellular
pertussis vaccines has been shown to improve short-term
vaccine efficacy in young children [38, 39]. In later studies,
it was also described as a correlation between IgG anti-
Fim2/3 and a reduced risk of disease [40, 41]. Although
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Figure 5: Specific IgG and IgA antibodies in BAL washes. Groups of animals were immunized intranasally or intraperitoneally three
times with PBS, CTB, rFim2, or CTB-Fim2 every 12 days followed by intranasal challenge with B. pertussis Tohama phase I strain of
(5 × 107 CFU/mouse). At 8 days postinfection, animals were euthanized and BAL washes were collected to determine the levels of anti-
Fim2 IgG (a) and IgA (b) antibodies. Antibody levels were assayed using ELISA. Values represent the OD at 492 nm and are representative
of two separate experiments ( ∗𝑃 < 0.05 versus CTB-Fim2 IP, ∗∗𝑃 < 0.001 and 𝑃 < 0.0001 versus PBS, CTB, and rFim2 IN, ∘𝑃 < 0.05 versus
PBS and CTB, +𝑃 < 0.05 versus PBS, CTB, and rFim2 IN and IP, and ++𝑃 < 0.001 versus CTB-Fim2 IP).
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Figure 6: IgG1 and IgG2a antibody isotype response. Comparison
of the serum anti-Fim2 IgG1 and IgG2a levels induced by PBS,
CTB, rFim2, or CTB-Fim2 via the intranasal (IN) route. Sera were
collected from mice on day 36. The anti-Fim2 IgG1 and IgG2a titers
were determined using ELISA. Data are expressed as the mean
(±standard error) absorbance at 492 nm for each group. Statistical
differences were observed in different comparisons (IgG1 CTB-
Fim2 versus all other categories except rFim2 ∗∗∗𝑃 < 0.0001, rFim2
versus all other categories except CTB-Fim2 +++𝑃 < 0.0001, and
IgG2a CTB-Fim2 versus all other categories ∘∘∘𝑃 < 0.0001).
it has been well established that Fim2 purified from B.
pertussis confers protection against infection in the mouse
respiratorymodel [20], mice intraperitoneal immunizedwith
the recombinant protein (rFim2) are not protected against
challenge with B. pertussis [42]. The molecular basis of this
difference has not been established, but it could be due
to differences in the structure of Fim2 obtained from the
two sources. Furthermore, the protective capacity of rFim2
delivered mucosally has not been reported previously.
Here we constructed CTB-Fim2 to explore Fim2
immunogenicity exploiting the adjuvant properties of the
CTB molecule. CTB has been widely used as an adjuvant in
rodent studies [13, 14]. When given via the oral or intranasal
route, CTB not only elicits anti-CTB responses at multiple
mucosal sites but also induces strong antibody responses
to genetically fused administered antigens [32]. Previous
studies have successfully tested the possibility of intranasal
immunization with an acellular pertussis vaccine using CTB
as an adjuvant, mixing recombinant CTB with pertussis
toxoid and formalin-treated filamentous hemagglutinin [43].
Furthermore, a chimeric protein consisting of a divalent
pertussis toxin (PTX) S1 fragment linked to the cholera
toxin A2B fragment elicited protective immunity after three
intranasal immunizations, showing the potent effect of CT
as a mucosal adjuvant [44].
The CTB-Fim2 presented here formed a pentameric
structure that seemed to be important in relation to its adju-
vant capacity [13]. More importantly, a significant reduction
in the number of bacteria recovered from the lungs was
observed in mice immunized with CTB-Fim2 compared to
those immunized with rFim2 or the control mice groups
indicating that some antigen can offer protection when fused
to CTB. The protective capacity of CTB-Fim2 over rFim2
may be due, at least in part, to both the increased uptake of
coupled antigen across the mucosal barrier [45] and more
efficient delivery to antigen-presenting cells [46]. In our
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Figure 7: Cytokine mRNA expression levels in lung. Groups of animals were immunized intranasally three times with PBS, CTB, rFim2, or
CTB-Fim2 every 12 days followed by intranasal challenge with 5 × 107 UFC of the Tohama I strain of B. pertussis. At 8 days postinfection,
animalswere killed and lung sampleswere collected formeasuringmRNA levels of IFN-𝛾 (a) and IL-4 (b). Statistical differenceswere observed
between CTB-Fim2 and all other groups except rFim2 (𝑃 < 0.001).
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Figure 8: Representative lung sections of BALB/cmice afterB. pertussis challenge.Mild lung inflammation in PBS (a) andCTB (b) immunized
mice. Moderate lung inflammation in Fimb2 immunized animals (c). More severe lung inflammation with extensive cell exudate and some
consolidation (pneumonia) was observed in lungs of CTB-Fimb2 immunized animals (d). Hematoxilin-eosin staining in all cases. ×150
magnifications.
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conditions and in agreement with other authors [42], rFim2
alone was not a good immunogen to reduce bacterial burden
in lungs when administered via either the intraperitoneal or
the intranasal route.
We also observed that intranasal immunization with
CTB-Fim2 induced similar levels of anti-Fim2 serum IgG
to those of intraperitoneal immunization. Furthermore,
intranasal immunization with CTB-Fim2 induced high levels
of anti-Fim2 IgG in BAL, indicating that both CTB-Fim2 and
intranasal administration of the immunogen are adequate to
induce a strong IgG response in the lungs.
Since one of the hallmarks of mucosal immunity is the
production of secretory IgA, which acts to prevent bacterial
and viral infection, and since CTB is capable of inducing spe-
cific IgA [47–51] by synergism with MyD88-dependent TLR
signals which selectively imprint a IgA-inducing capacity in
nonmucosal DCs [52], we studied this immunoglobulin in
CTB-Fim2-immunized mice and verified that mice adminis-
teredCTB-Fim2 elicited specific Fim2-IgA inBAL.This result
was not observedwith the other treatments performed herein
and is consistent with previously published data showing that
parenteral administration is less effective thanmucosal routes
in inducing mucosal responses important for protection
[53]. In transcutaneous and intranasal immunization with
a Chlamydia muridarum antigen, higher levels of specific
IgG were induced in serum and BAL, while only intranasal
immunization induced specific IgA in BAL using CTB as an
adjuvant [54]. It seems that CTBmay directly cause B cells to
enhance S-IgA production [55] and the IgA isotype switching
through TGF-𝛽1 [56].
In mice that were immunized by mucosal administration
of CTB-Fim2, we observed a comparable rise of IgG1 and IL4
mRNA levels and enhanced IgG2a and IFN-𝛾mRNA levels as
well as an increased inflammatory cell exudate.The enhanced
inflammatory response in vaccinated mice, in agreement
with other studies [57], may represent an enhanced host
response to clear the bacteria. Taken together, the results
showed that rFim2 results mainly in a Th2 response, as
observed with aP vaccines [4], and that when rFim2 is fused
to CTB, results in a mixed Th1/Th2 response, consistent
with similar observations reported by others [58, 59] and
improving one of the shortcomings observed in aP vaccines
[60].
5. Conclusions
In conclusion, the results presented herein show that CTB is
a potent adjuvant that when fused to Fim2 enhances their
immunogenicity, stimulating both systemic and mucosal
immune responses resulting in a mixed Th1/Th2 T-helper
response. Having in mind the concerns that arose by the
intranasal use of CTB and its subsequent accumulation in
the olfactory bulb of mice [61] and that some vaccines
administrated by the intranasal route have been associated
with Bell’s palsy in humans [62], the fact that CTB-Fim2
administrated by the intraperitoneal route also offers pro-
tection, supports its value as a protective immunogen. In
addition, open the possibility to be used by other routes, even
mucosal routes, as have been done with CTB fused to other
antigens in preclinical studies [63] as well as in humans (CTB
administered by mucosal way in healthy adult volunteers,
trial NCT00820144, NIH, publication pending). Therefore,
the genetic fusion of ctb and fim2 genes provides a new
promising antigen against Bordetella pertussis infection.
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